MedAdvisor Limited EBIT

The latest EBIT for MDR.AX is $-58M as of June 2025. That compares with $-25M in the prior-year period — down 134.4% year over year. That is below the sector sector average of $-25M. Investors often review this figure alongside MedAdvisor Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, MDR.AX's EBIT moved from $-25M to $-58M — a 134.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in MedAdvisor Limited's operating scale or balance-sheet position.

Against its sector companies, MDR.AX currently prints $-58M for EBIT, while the sector average sits near $-25M. That is roughly 127.6% below the sector mean. Large gaps often invite a closer look at MedAdvisor Limited's growth, margins, and balance sheet.

A EBIT figure of $-58M for MDR.AX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-25M. Explore the charts below for those layers of context.

After noting MDR.AX's EBIT ($-58M), review year-over-year change from $-25M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.